Baricitinib for treating severe alopecia areata

4.1 The results of the BRAVE trials showed that almost half of the people with severe alopecia areata had scores of full health, measured by the EQ‑5D‑5L at baseline. In addition, compared with the baseline scores, no improvement in EQ‑5D‑5L scores were observed after treatment. The company also provided EQ‑5D‑5L data from the Adelphi study (a real-world study), that also showed a large proportion of people with alopecia areata reporting scores of full health.

4.2 Further research is recommended to resolve the uncertainties about the validity and responsiveness of the EQ‑5D in alopecia areata and explore whether there are preferable health-related quality-of-life measures for this condition.